Recipient of the '2005 Golden Spire Outstanding Business of the Year' Award

Novato, Calif., November 14, 2005 -- BioMarin Pharmaceutical Inc., a Marin County-based biopharmaceutical company, announced today that it has been named Business of the Year by the Marin County Board of Supervisors. The company will be presented with the "2005 Golden Spire Outstanding Business of the Year" award at the Seventh Annual Awards of Excellence luncheon to take place on November 18, 2005.

"We are honored to have been recognized by the Board of Supervisors for the work we do within the rare disease community and within our local community," stated Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "Since our founding in Novato approximately eight years ago, we have grown from a company with 15 employees, to one with over 300 employees and three products on the market. We appreciate the support we have received from the local community, especially with our annual 'BioMarin/MPS Run for Your Life' fun run benefiting The National MPS Society, and look forward to what lies ahead both for BioMarin and the local community."

The Golden Spire Award is granted in recognition of a Marin County-based company that makes a significant contribution to the County's economic vitality and is exemplary in demonstrating corporate responsibility in terms of progressive practices, environmental sensitivity, and generosity in giving back to the community. Past recipients include Lucasfilm, Fireman's Fund Insurance Company, Autodesk, Marin Independent Journal and Mollie Stone's.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution) for inflammatory conditions. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit www.BMRN.com.

Information on BioMarin's website, www.BMRN.com, is not incorporated by reference into this press release.

  Contacts:

   Joshua A. Grass                         Susan Ferris
   BioMarin Pharmaceutical Inc.            BioMarin Pharmaceutical Inc.
   415-506-6777                            415-506-6701

PRNewswire -- Nov. 14

SOURCE: BioMarin Pharmaceutical Inc.